Involvement of pulmonary arteriopathy in the development and severity of reperfusion pulmonary edema after pulmonary endarterectomy

Takayuki Jujo Sanada1,2, Nobuhiro Tanabe1,2, Hatsue Ishibashi-Ueda3, Keiichi Ishida4, Akira Naito1, Seiichiro Sakao1, Rika Suda1, Hajime Kasai1, Rintaro Nishimura1, Toshihiko Sugiura1, Ayako Shigeta1, Yu Taniguchi1,5, Masahisa Masuda4 and Koichiro Tatsumi1

1Department of Respirology (B2), Graduate School of Medicine, Chiba University, Chiba, Japan; 2Department of Advanced Medicine in Pulmonary Hypertension, Graduate School of Medicine, Chiba University, Chiba, Japan; 3Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan; 4Department of Cardiovascular Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan; 5Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Chuo-Ku, Kobe, Japan

Abstract
Reperfusion pulmonary edema (RPE) is a common complication after pulmonary endarterectomy (PEA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, the precise mechanisms underlying the development of RPE remain unclear. To evaluate the effects of pulmonary vasculopathy on RPE, the severity of the pulmonary arteriopathies and venopathies of lung tissues biopsied during PEA were pathologically quantified in 33 CTEPH patients. The severity of RPE was classified from grade 0 (no RPE) to 4 (death due to RPE) based on the arterial oxygen tension/inspiratory oxygen fraction (P/F ratio) and necessity of respiratory management. Among the 33 patients (27 women; mean age = 63.3 years), 17 (51.5%) patients developed RPE. The severity of pulmonary arteriopathy (obstruction ratio) correlated with the grade of RPE (r = 0.576, P = 0.0005). The obstruction ratio also correlated with the P/F ratio (r = −0.543, P = 0.001) and the perioperative mean pulmonary arterial pressure (r = 0.445, P = 0.009). Multivariate logistic regression analysis revealed that the obstruction ratio was a significant independent determinant for the development of RPE (odds ratio = 15.7; 95% confidence interval = 2.29–108.00, P = 0.005). In conclusion, pulmonary arteriopathy could be a determinant of the development and severity of RPE after PEA.

Keywords
chronic thromboembolic pulmonary hypertension, residual hypertension, hypoxia, complication

Corresponding author:
Takayuki Jujo Sanada, Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-Ku, Chiba City 260-8670, Japan.
Email: naikamo_resp19184@chiba-u.jp

Chronic thromboembolic pulmonary hypertension (CTEPH) is a subtype of pulmonary hypertension (PH) characterized by occlusion of pulmonary arteries due to chronic thromboemboli.1,2 Pulmonary endarterectomy (PEA) surgery, which is the main treatment for CTEPH patients, removes the chronic thrombi from the pulmonary arteries.1 Reperfusion pulmonary edema (RPE) is a major complication of PEA. RPE is lung edema in the lung area in which the blood perfusion improved after PEA.3 The occurrence of RPE is 8–91%,3,7 which varies by criteria of RPE.4,7 Patients with severe RPE often require prolonged
mechanical ventilation and hospitalization in the intensive care unit (ICU). The mechanisms of RPE appear to include endothelial damage and enhanced vascular permeability related to reperfusion after ischemia. However, the detailed mechanisms underlying the development of RPE remain unclear. Clinically, the presence of severe PH before PEA and residual PH after PEA are considered risks factors for the development of RPE. We previously reported a close association between pulmonary arteriopathy and residual PH. Therefore, we hypothesized that pulmonary arteriopathy could be associated with the development of RPE. The purpose of this study was to evaluate whether pulmonary arteriopathy or venopathy is associated with the development of RPE and to understand the pathogenesis of RPE.

Methods

The Ethics Committee of Chiba University approved this study (approval no. 1221). All patients provided written informed consent.

Participants

Between December 2011 and August 2016, 51 CTEPH patients underwent PEA at Chiba University Hospital. Lung biopsy was performed in 35 patients. Of the 35 patients, two were excluded from the study because the specimens were too small for detailed pathological analysis. Thus, clinical and pathological data from 33 patients were retrospectively analyzed. Determination of a definitive diagnosis and an examination including right heart catheterization were performed at the preoperative period and a complete examination was performed one month and one year after PEA in all patients, as previously reported. The hemodynamic data soon after PEA were collected from the patients’ ICU records. The hemodynamic data were measured using CCOmbo Catheters (774F75, Edwards Lifesciences, Irvine, CA, USA). The mean pulmonary arterial pressure (mPAP) in the ICU and continuous cardiac output was defined as the pressure at the onset of RPE in patients with RPE or the pressure 5–6 h after PEA in patients without RPE.

Pulmonary endarterectomy

PEA was performed by KI and MM at Chiba University Hospital. The indications for PEA were as follows: (1) mPAP ≥ 25 mmHg; (2) pulmonary vascular resistance (PVR) > 300 dyne-s-cm⁻²; (3) World Health Organization (WHO) functional class ≥ 2; (4) technically operable; (5) no significant co-morbidity; and (6) full understanding of the benefits and the risks. The Jamieson’s classification was determined during the operation by two experienced cardiovascular surgeons (KI and MM), as previously reported.

Reperfusion pulmonary edema

We diagnosed RPE based on the definition described by Jenkins, et al.: (1) arterial oxygen tension/inspiratory oxygen fraction (P/F ratio) < 300; (2) presence of infiltrative shadow on a chest radiograph in a reperfused lung area after PEA; and (3) no obvious cause of the symptoms, such as pulmonary bleeding, atelectasis, or pneumonia. The P/F ratio analyzed in this study was the value at the diagnosis of RPE in patients with RPE or 5–6 h after PEA in those without RPE. Two trained respiratory physicians (TJ-S and AN) interpreted the chest radiography images. The weighted kappa coefficient of the inter-observer agreement was 0.9495. Anesthetists checked whether airway bleeding exist by bronchoscopy during PEA. In the current study, no patient had relevant airway bleeding. The severity of RPE was graded based on the P/F ratio and the required respiratory management, and defined as follows: grade 0 = absence of RPE; grade 1 = presence of RPE, only typical respiratory management required; grade 2 = presence of RPE, respiratory management with positive end-expiratory pressure (non-invasive positive-pressure ventilation and/or nasal high flow) required; grade 3 = presence of RPE, prolonged artificial ventilation or extracorporeal membrane oxygenation required; and grade 4 = presence of RPE related to perioperative death. To prevent reperfusion lung edema, we used low dose of catecholamine to avoid high cardiac output and maintained water balance negative with aggressive use of diuretics. The patients were extubated as early as possible if oxygenation was maintained with PaO₂ > 80 mmHg. The extubation was typically conducted on post-operative day 1 and then oxygen was supplied by venturi masks or nasal cannulas. Non-invasive positive-pressure ventilation was applied if PaO₂ > 60 mmHg was not achieved with the venturi mask. The requirement of other respiratory management depended on the decision of the cardiovascular surgeons and clinicians in the ICU.

Lung biopsy

Lung specimens were biopsied from the right middle lobe or left lingular segment during PEA. Lung biopsy was limited to a single sample for safety and ethical reasons. In this study, pneumothorax that was potentially associated with the lung biopsy occurred in two of 33 patients (6.1%); both patients improved within a few days following thoracic drainage. The biopsied lung tissue was prepared based on methods described previously. In total, 781 slices were prepared, stained using the Elastica-van Gieson method, and analyzed pathologically, as described in the following section.

Quantification of pulmonary arteriopathy and venopathy

Two trained investigators (TJ-S and HI-U) conducted a pathological evaluation of pulmonary arteriopathy and venopathy based on methods described previously.
All pulmonary muscular arteries with adjacent bronchioles were recorded. The inclusion criteria of pulmonary arteries in the current study were as follows: (1) the horizontal-to-vertical ratio of these vessels was <1:2; and (2) the vascular diameter was <300 μm. The ratios of the intimal and medial area to the vascular area of the pulmonary arteries were evaluated in all arteries and the obstruction ratio of each patient was defined as the average of the ratios. Pulmonary veins were identified based on the following criteria: (1) vessels running into the interlobular septa; and (2) vessels with thick external elastic layers and unclear internal elastic layers. The extent of remodeling of each pulmonary vein (PV) was scored as follows: 0 = almost normal; 1 = slight; 2 = mild (<50% obstruction); 3 = moderate (>50% obstruction and/or muscularization); and 4 = severe (>80% obstruction). The PV score of each patient was defined as the average of the scores.

Quantification of segmental pulmonary thrombi

The extent of the segmental pulmonary arterial thrombi was evaluated using enhanced computed tomography (CT) based on methods described previously. Each segmental pulmonary artery was scored as follows: 0 = no thrombi; 1 = narrowed but contrast medium passed; or 2 = obstructed. The average of the scores obtained from each patient was defined as the segmental obstruction index. Two trained investigators (TJ-S and AN) examined a total of 91 CT images in a blind manner. There was a significant correlation between the scores of the two investigators (r = 0.888, P = 9 × 10⁻³²).

Quantification of bronchial arteries

Recently, it was reported that transcatheter occlusion of the bronchial arteries (BAs) before PEA might prevent RPE. In order to evaluate the relationship between the enlargement of the BAs and the development of RPE, the size of the bronchial arteries was quantified using enhanced CT scans based on the methods used in our previous study. The diameter of each BA was measured at its origin and the cross-sectional area was calculated. The sum of the cross-sectional areas in each patient was defined as the total area of the BAs.

Statistical analysis

Continuous variables are described as the mean ± standard deviation unless otherwise stated. Correlations between variables were evaluated using Spearman’s rank correlation coefficient. The time-dependent change of the variables was evaluated using the Wilcoxon signed rank test. Differences between three or more groups were evaluated using the Kruskal–Wallis test, adjusted using the Bonferroni method for multiple comparisons. Logistic regression analysis was performed to evaluate the factors associated with the development of RPE. A P value < 0.05 was considered significant. All data were analyzed using EZR (ver. 1.37, Saitama Medical Center, Jichi Medical University, Saitama, Japan).

Results

Patient characteristics

The characteristics of the 33 patients are shown in Table 1. One patient died 15 days after PEA due to sudden respiratory failure. Though the cause of death was unclear, there was no RPE during the perioperative period. mPAPs for the four periods are shown below: before PEA = 46.3 ± 10.7 mmHg; in the ICU = 28.5 ± 7.2 mmHg; one month after PEA = 25.7 ± 8.6 mmHg; and one year after PEA = 26.5 ± 8.5 mmHg. In comparison with the PAP before PEA, the mPAP significantly decreased at all of the

| Table 1. Patient characteristics. |
|----------------------------------|
| Patients (n) | 33                        |
| Age (years) | 63.3 ± 8.5                |
| Sex (M:F)   | 6:27                      |
| Duration from onset to PEA (months) | 63.7 ± 58.6             |
| Jamieson's classification (%) |                          |
| 1           | 10 (30.3)                 |
| 2           | 16 (48.5)                 |
| 3           | 7 (21.2)                  |
| Circulatory arrest time (min)   | 54.9 ± 18.0              |
| Preoperative data               |                           |
| mPAP (mmHg) | 46.3 ± 10.7               |
| PVR (dyne·s·cm⁻⁵) | 763 ± 306               |
| Cl (L/min/m²) | 2.85 ± 0.69              |
| PAWP (mmHg) | 7.9 ± 2.7                 |
| PaO₂ (mmHg) | 57.4 ± 9.4                |
| %DLCO/VA (%) | 80.8 ± 16.3             |
| Hemodynamics in ICU            |                           |
| mPAP (mmHg) | 28.5 ± 7.2                |
| ΔmPAP (mmHg) | 17.8 ± 11.3              |
| Continuous Cl (L/min/m²) | 2.05 ± 0.42               |
| Vascular remodeling             |                           |
| Obstruction ratio               | 0.850 ± 0.139             |
| PV score                        | 1.10 ± 0.41               |
| Bronchial arteries              |                           |
| Total BA area (mm²)            | 8.1 ± 4.1                 |
| Segmental pulmonary arteries    |                           |
| SGOI                            | 0.37 ± 0.14               |
| Perioperative death (%)         | 1 (3.0)                   |

PEA, pulmonary endarterectomy; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; CI, cardiac index; PAWP, pulmonary arterial wedge pressure; ICU, intensive care unit; PV, pulmonary vein; BA, bronchial artery; SGOI, segmental obstruction index.
following time points: in the ICU ($P = 1.4 \times 10^{-9}$); one month after PEA ($P = 5.8 \times 10^{-11}$); and one year after PEA ($P = 1.8 \times 10^{-11}$) (Fig. 1a). However, there was no statistical difference in the mPAP between the three periods after PEA: in the ICU versus one month after PEA ($P = 0.3$); in the ICU versus one year after PEA ($P = 0.6$); and one month and one year after PEA ($P = 1.0$) (Supplemental Table). The mPAP was positively correlated with those of one month and one year after PEA: one month after PEA ($r = 0.652, P = 0.001$); and one year after PEA ($r = 0.611, P = 0.0003$) (Fig. 1b and 1c).

Reperfusion pulmonary edema

All infiltrations were found in lung areas from which chronic thrombi were removed. RPE occurred in 17 of 33 cases (51.5%). The distribution of the RPE grade was as follows: grade 0 = 16 cases (48.5%); grade 1 = two cases (6.1%); grade 2 = 10 cases (30.3%); grade 3 = five cases (15.2%); and no patients had grade 4 RPE (Fig. 2a). The onset of RPE occurred on the day of PEA in 16 of 17 patients (94.1%) and on postoperative day 1 in one patient (5.9%). The mPAP in the ICU was positively correlated with the RPE grade ($r = 0.657, P = 0.00003$, Fig. 2b).

Pulmonary arteriopathy and venopathy

Pulmonary arteriopathy and venopathy were observed in all 33 cases (Fig. 3). In this study, 406 PAs (12.3 per patient and 0.52 per section) and 6382 PVs (193 per patient and 8.2 per
section) were examined in 781 slides from 33 cases. The average PA diameter was 170.3 ± 59.8 μm (range = 52.1–297 μm) and the average obstruction ratio was 0.850 ± 0.139. The distribution of the PV scores was as follows: 0 = 25.9 ± 19.5%; 1 = 44.7 ± 12.8%; 2 = 23.9 ± 14.1%; 3 = 4.4 ± 5.1%; and 4 = 1.0 ± 2.6%. The average PV score was 1.10 ± 0.41%. Pathological findings, including pulmonary edema or capillary changes such as pulmonary capillary hemangiomatosis, were not found in any cases.

Hemodynamic change after PEA and the effect of pulmonary arteriopathy

The obstruction ratio was positively correlated with the mPAP obtained in the ICU (r = 0.445, P = 0.009; Fig 4) as well as the mPAP before, one month after, and one year after PEA: before PEA (r = 0.499, P = 0.003); one month after PEA (r = 0.433, P = 0.02); and one year after PEA (r = 0.498, P = 0.004).
The relationship between pulmonary arteriopathy and the severity of RPE

The obstruction ratio and the mPAP in the ICU of patients with grade 3 RPE were significantly higher than those of patients without RPE (grade 0) (Table 2). The PV scores were not significantly different among the different RPE grades (P = 1.0) and neither were the preoperative clinical data, including the total area of BAs, among the RPE grades. The obstruction ratio was positively correlated with the RPE grade (r = 0.576, P = 0.0005; Fig. 4a) and negatively correlated with the P/F ratio (r = −0.543, P = 0.001; Fig. 4b). The obstruction ratio was also positively correlated with the mPAP obtained in the ICU (r = 0.445, P = 0.009; Fig. 4c).

Determinant for developing RPE

The logistic regression analysis demonstrated that the obstruction ratio was associated with the development of RPE (Table 3). Next, we determined whether the obstruction ratio and postoperative mPAP were associated with the onset of RPE using a multivariate analysis. The analysis revealed that the obstruction ratio was a significant independent determinant for the development of RPE (odds ratio [OR] = 15.7; 95% confidence interval [CI] = 2.29–108.00, P = 0.005) as well as the postoperative mPAP (OR = 7.35; 95% CI = 1.03–52.70, P = 0.047) (Table 3).

Discussion

In this study, we evaluated the clinical and pathological factors associated with the development of RPE. We found that the obstruction ratio was a determinant for the development of RPE. In addition, the obstruction ratio was significantly correlated with the severity of RPE, P/F ratio, and mPAP after PEA. The preoperative clinical variables, including the total area of the BAs, were not associated with the development or severity of RPE.

In the current study, the obstruction ratio was found to be a predictor of RPE, independent of the mPAP values. There are two types of PH after PEA that can influence the development of PEA. Reversible PH after PEA can result from pulmonary vasoconstriction due to mechanical and/or reperfusion injury; this commonly improves within 72 h after PEA. Residual PH, which can be irreversible and persistent, may result from severe pulmonary arteriopathy.

In the current study, mPAP in the ICU was positively correlated with the RPE grade and did not improve one month or one year after PEA. The long-term data of the current and previous study showed that the obstruction ratio was closely related with poor hemodynamics both soon after PEA and at one month and one year after PEA. Thus, it was supposed that residual PH due to severe pulmonary arteriopathy could be a key factor in RPE development. Consistent with our findings, Stephan et al. reported that poor improvement of PVR just after PEA and a lower P/F ratio were correlated with severe exudation of extravascular lung water. Reperfusion to ischemic lung tissue could cause increased shear stress and endothelial damage, resulting in extravasation. It could be that the residual PH associated with severe pulmonary arteriopathy induces increased

Fig. 4. Correlation between pulmonary arteriopathy and reperfusion pulmonary edema (RPE). (a) The obstruction ratio was positively correlated with the severity of RPE (r = 0.576, P = 0.0005). (b) The obstruction ratio was negatively correlated with the arterial oxygen tension/inspiratory oxygen fraction (P/F ratio) (r = −0.543, P = 0.001). (c) The obstruction ratio was positively correlated with the perioperative mPAP (r = 0.445, P = 0.009).
sheer stress and lung injury following PEA. Persistent hypoxemia after PEA, partly due to ventilation/perfusion mismatch and impaired diffusion capacity, would be associated with severe pulmonary arteriopathy. Therefore, the exudation of extravascular lung water showing infiltration in the lung area aggravates the ventilation/perfusion mismatch and diffusion capacity, thereby inducing an impaired P/F ratio after PEA.

Whether bronchial artery transformation is related to the development of RPE was unclear in our study. It was hypothesized that the enlargement of the BAs might be related to the development of RPE in the current study. It was shown that the BAs of CTEPH patients are enlarged and that shunts between the pulmonary and bronchial arteries exist. It was reported that the cross-sectional area measured by using CT images could be positively correlated with the shunt blood volume and the collateral blood flow increased in patients with CTEPH compared with the levels in pulmonary arterial hypertension patients or healthy volunteers. Gan et al. suggested that preoperative occlusion of enlarged BAs might prevent patients from developing RPE. In contrast to those reports, enlargement of the BAs was not found to be associated with the development or severity of RPE in the current study. The reason for this discrepancy remains unclear.

Pulmonary venopathy was not related to the development of RPE in this study. Pulmonary veno-occlusive disease is a subtype of PH characterized by the severe remodeling of PVs. Increased blood flow caused by specific pulmonary vasodilators could induce pulmonary edema in patients with pulmonary veno-occlusive disease. In the current study, approximately 95% of PVs in CTEPH patients remained normal or mild. This may explain the limited effects of the PVs on the development of RPE.

The present study had several limitations. First, this study was conducted with a small sample size at a single institution and all participants were Japanese. Second, respiratory management depended on the decision of the cardiac surgeons and staff in the ICU. This might have affected the severity of RPE. Third, since lung biopsy is an invasive procedure, we do not recommend routine lung biopsy before PEA. In this study, we felt that the alternative methods for evaluating the pulmonary microcirculation

| Table 2. Comparison of patient characteristics among RPE grades. |
|---------------------------------|
| RPE grade | 0 | 1 | 2 | 3 | 4 |
| Cases     | 16 | 2 | 10 | 5 |  |
| Age (years) | 61.7 ± 9.9 | 69.0 ± 5.7 | 61.8 ± 6.9 | 69.2 ± 4.2 | 0.20 |
| Sex       | Male | 3 | 0 | 2 | 1 | 1.0 |
| Female | 13 | 2 | 8 | 4 |  |
| Duration from onset to PEA (months) | 44.0 ± 40.3 | 143.0 ± 24.0 | 89.3 ± 73.5 | 44.0 ± 47.3 | 0.2 |
| Circulatory arrest time (min) | 49.1 ± 14.7 | 48.5 ± 0.7 | 64.7 ± 19.7 | 56.4 ± 22.5 | 0.2 |
| Preoperative data            |     |     |     |     |  |
| mPAP (mmHg)                  | 42.4 ± 10.9 | 50.0 ± 15.6 | 50.7 ± 10.8 | 48.4 ± 4.8 | 0.2 |
| PVR (dyne-s-cm⁻¹)            | 671 ± 299 | 1030 ± 586 | 864 ± 303 | 750 ± 158 | 0.4 |
| CI (L/min/m²)                | 2.98 ± 0.81 | 2.77 ± 0.37 | 2.71 ± 0.47 | 2.76 ± 0.80 | 0.8 |
| PAWP (mmHg)                  | 8.6 ± 2.5 | 6.0 ± 1.4 | 6.4 ± 2.2 | 9.6 ± 3.2 | 0.07 |
| PsO₂ (mmHg)                  | 58.6 ± 11.0 | 63.8 ± 14.9 | 53.2 ± 4.8 | 59.5 ± 8.8 | 0.5 |
| %DLCO/VA (%)                 | 77.3 ± 15.1 | 84.0 ± 8.1 | 87.9 ± 9.6 | 78.1 ± 28.6 | 0.2 |
| Hemodynamics in ICU          |     |     |     |     |  |
| mPAP (mmHg)                  | 24.7 ± 5.4 | 21.0 ± 0.0 | 30.9 ± 4.2* | 38.6 ± 6.4* | 0.001 |
| ΔmPAP (mmHg)                 | 17.7 ± 11.6 | 29.0 ± 15.6 | 19.8 ± 9.4 | 9.8 ± 10.1 | 0.3 |
| CCI (L/min/m²)               | 2.05 ± 0.46 | 2.06 ± 0.15 | 2.19 ± 0.39 | 1.75 ± 0.35 | 0.2 |
| Vascular remodeling          |     |     |     |     |  |
| Obstruction ratio            | 0.791 ± 0.135 | 0.837 ± 0.061 | 0.901 ± 0.150 | 0.946 ± 0.044* | 0.01 |
| PV score                     | 1.08 ± 0.44 | 1.08 ± 0.01 | 1.13 ± 0.40 | 1.11 ± 0.46 | 1.0 |
| Bronchial arteries            |     |     |     |     |  |
| Total BA area (mm²)          | 7.92 ± 3.66 | 7.51 ± 0.49 | 8.44 ± 4.65 | 7.97 ± 5.86 | 1.0 |
| SGOI                         | 0.35 ± 0.15 | 0.44 ± 0.04 | 0.40 ± 0.11 | 0.33 ± 0.19 | 0.5 |

*aP < 0.05 vs. RPE grade 0. See Table 1 for abbreviations.
were needed. Fourth, the number of PEA cases in our institution was relatively small. It was reported that the number of PEAs per year could be related to the postoperative prognosis;\(^2\) therefore, the relative lack of experience at our institution might have affected the occurrence and severity of RPE. Fifth, the obstruction ratio might vary by the amount of occlusion in the proximal pulmonary arteries. It was reported that remodeled pulmonary arteries were identified not only in the open vascular area but also in the occluded area.\(^1\) With additional analysis, there was no significant correlation between the SGOI at the biopsied segments and the obstruction ratio (\(r = 0.03, \ P = 0.8\); data not shown.). Finally, the resected lung specimens were small and only one specimen was obtained from each patient. It is unclear whether small samples may reflect the condition of the entire lung. Dorfmüller et al. described that remodeled pulmonary arteries were identified on all of the 170 slides randomly selected from the peripheral lung area of CTEPH patients.\(^1\) In this study, we felt that the random sampling of pulmonary arteries using the single lung biopsy specimens could provide important information. Despite these limitations, we believe that our analysis is able to partially explain the mechanisms involved in the development of RPE after PEA. As a future treatment strategy, it seems that the reverse remodeling of pulmonary arteries before PEA might help to reduce the development of RPE.

In conclusion, severe pulmonary arteriopathy could be a key factor in the development and severity of RPE after PEA.

### Table 3. Logistic regression analysis for the development of RPE.

| Factor                      | Univariate analysis | P value | Multivariate analysis | P value |
|-----------------------------|---------------------|---------|-----------------------|---------|
|                            | OR (95% CI)         |         | OR (95% CI)           |         |
| Age \(\geq 64^{th}\) years | 1.11 (0.28–4.42)    | 0.88    | 7.35 (1.03–52.70)     | 0.047   |
| Sex: Male                   | 0.93 (0.16–5.45)    | 0.94    |                       |         |
| Disease duration \(\geq 36^{th}\) months | 1.84 (0.46–7.31)    | 0.39    |                       |         |
| Jamieson’s classification: type 3 | 0.64 (0.12–3.46)  | 0.61    |                       |         |
| Circulatory arrest time \(\geq 55^{th}\) min | 1.12 (0.29–4.41)    | 0.87    |                       |         |
| Preoperative mPAP \(\geq 48^{th}\) mmHg | 1.84 (0.46–7.31)    | 0.39    |                       |         |
| Preoperative PVR \(\geq 757^{th}\) dyne/s/cm\(^5\) | 1.84 (0.46–7.31)    | 0.39    |                       |         |
| Preoperative CI \(\geq 2.65^{th}\) L/min/m\(^2\) | 0.42 (0.10–1.70)    | 0.22    |                       |         |
| Postoperative mPAP \(\geq 26^{th}\) mmHg | 10.30 (2.00–52.70)  | 0.0052  | 7.35 (1.03–52.70)     | 0.047   |
| \(\Delta mPAP \geq 18.3^{th}\) mmHg | 0.69 (0.18–2.73)    | 0.6     |                       |         |
| Postoperative CI             | 0.78 (0.18–3.28)    | 0.7     |                       |         |
| Preoperative PaO\(_2\) \(\geq 56.8^{th}\) mmHg | 1.45 (0.37–5.70)    | 0.6     |                       |         |
| Preoperative %\(\% DL_{CV}/VA \geq 80.1^{th}\) % | 1.47 (0.36–6.05)    | 0.59    |                       |         |
| Obstruction ratio \(\geq 0.88^{th}\) | 20.20 (3.45–119.00) | 0.00087 | 15.70 (2.29–108.00)   | 0.0051  |
| PV score \(\geq 1.07^{th}\) | 0.69 (0.18–2.73)    | 0.6     |                       |         |
| Total area of BA \(\geq 7.60^{th}\) mm\(^2\) | 1.65 (0.41–6.68)    | 0.48    |                       |         |
| SGOI \(\geq 0.38^{th}\) | 4.00 (0.94–17.10)   | 0.062   |                       |         |

*Median values. See Table 1 for abbreviations.

### Acknowledgments

The authors thank Editage (www.editage.jp) for English language editing.

### Conflict of interest

TJ is a member of an endowed department sponsored by Actelion Pharmaceuticals Ltd.; NT is a member of an endowed department sponsored by Actelion Pharmaceuticals Ltd. and received lecture honoraria from Bayer AG, Daiichi-Sankyo Company, Limited, Actelion Pharmaceuticals Ltd. and Nippon Shinyaku Co., Ltd; AN is a member of the Joint Collaborative Department with Teijin Pharma, Ltd. and Ono Pharmaceutical, Ltd.; SS received honoraria for lectures from Nippon Shinyaku Co., Ltd, Bayer, Actelion Pharmaceuticals, and Pfizer. AS is a member of an endowed department sponsored by Actelion Pharmaceuticals Ltd.; YT received a research grant from Actelion Pharmaceuticals Ltd. and lecture honoraria from Nippon Shinyaku Co., Ltd; and KT received lecture honoraria from Actelion Pharmaceuticals Ltd. The other authors had no potential conflicts of interest.

### Funding

This study was supported by the Japanese Ministry of Health, Labour and Welfare research grants specifically designated to the Respiratory Failure Research Group and Cardiovascular Diseases and the Pulmonary Hypertension Research Group from the Japan Agency for Medical Research and Development (No. 16ek0109127h0002). The funder had no role in the study’s design, collection of data or their analysis, decision to publish, or preparation of the manuscript.
References

1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–975.

2. Tanabe N, Sugiu T, and Tatsumi K. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension. Respir Investig 2013; 51: 134–146.

3. Jenkins DP, Madani M, Mayer E, et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2013; 41: 735–742.

4. Levinson RM, Shure D and Moser KM. Reperfusion pulmonary edema after pulmonary artery thromboendarterectomy. Am Rev Respir Dis 1986; 134: 1241–1245.

5. Dartevelle P, Fadel E, Chapelier A, et al. Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. Eur J Cardiothorac Surg 1999; 16: 38–43.

6. Thistlethwaite PA, Kemp A, Du L, et al. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2006; 131: 307–313.

7. Stéphan F, Mazeraud A, Laverdure F, et al. Evaluation of reperfusion pulmonary edema by extravascular lung water measurements after pulmonary endarterectomy. Crit Care Med 2017; 45: e409–e417.

8. Kerr KM, Auger WR, Marsh JJ, et al. Efficacy of methylprednisolone in preventing lung injury following pulmonary thromboendarterectomy. Chest 2012; 141: 27–35.

9. Jujo T, Sakao S, Ishibashi-Ueda H, et al. Evaluation of the microcirculation in chronic thromboembolic pulmonary hypertension patients: the impact of pulmonary arterial remodeling on postoperative and follow-up pulmonary arterial pressure and vascular resistance. PLoS One 2015; 10: e0133167.

10. Jujo T, Tanabe N, Sakao S, et al. Severe pulmonary arteriopathy is associated with persistent hypoxemia after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. PLoS One 2016; 11: e0161827.

11. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76: 1457–1462.

12. Gan HL, Zhang JQ, Sun JC, et al. Preoperative transcatheter occlusion of bronchopulmonary collateral artery reduces reperfusion pulmonary edema and improves early hemodynamic function after pulmonary thromboendarterectomy. J Thorac Cardiovasc Surg 2014; 148: 3014–3019.

13. Shimizu H, Tanabe N, Terada J, et al. Dilatation of bronchial arteries correlates with extent of central disease in patients with chronic thromboembolic pulmonary hypertension. Circ J 2008; 72: 1136–1141.

14. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–458.

15. Kramm T, Eberle B, Guth S, et al. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005; 28: 882–888.

16. Fischer S, Maclean AA, Liu M, et al. Dynamic changes in apoptotic and necrotic cell death correlate with severity of ischemia-reperfusion injury in lung transplantation. Am J Respir Crit Care Med 2000; 162: 1932–1939.

17. Fischer S, Cassivi SD, Xavier AM, et al. Cell death in human lung transplantation: apoptosis induction in human lungs during ischemia and after transplantation. Ann Surg 2000; 231: 424–431.

18. Dorflmuller P, Gunther S, Ghigna MR, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. Eur Respir J 2014; 44: 1275–1288.

19. Ley S, Kreitner KF, Morgenstern I, et al. Bronchopulmonary shunts in patients with chronic thromboembolic pulmonary hypertension: evaluation with helical CT and MR imaging. AJR Am J Roentgenol 2002; 179: 1209–1215.

20. Endrys J, Hayat N and Cherian G. Comparison of broncho-pulmonary collaterals and collateral blood flow in patients with chronic thromboembolic and primary pulmonary hypertension. Heart 1997; 78: 171–176.

21. Dai Z and Matsui Y. Pulmonary veno-occlusive disease: an 80-year-old mystery. Respiration 2014; 88: 148–157.

22. Huertas A, Girerd B, Dorfmuller P, et al. Pulmonary veno-occlusive disease: advances in clinical management and treatments. Expert Rev Respir Med 2011; 5: 217–229.

23. Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation 2016; 133: 859–871.

24. Moser KM and Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993; 103: 685–692.